2022
DOI: 10.1016/j.crfs.2022.10.031
|View full text |Cite
|
Sign up to set email alerts
|

Advances in the stability challenges of bioactive peptides and improvement strategies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
13
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 44 publications
(20 citation statements)
references
References 113 publications
1
13
0
Order By: Relevance
“…After absorption, bioactive peptides are often rapidly degraded by proteases or rapidly cleared in the plasma, kidneys, and liver. 29 Currently, chemical modifications and nano-delivery studies are being performed to investigate the metabolic process of these bioactive peptides in vivo . Bottger et al incubated eight peptides with the blood, plasma, and serum, and they found that the modified peptide with its C-terminal amide was more stable in the blood, plasma and serum.…”
Section: Resultsmentioning
confidence: 99%
“…After absorption, bioactive peptides are often rapidly degraded by proteases or rapidly cleared in the plasma, kidneys, and liver. 29 Currently, chemical modifications and nano-delivery studies are being performed to investigate the metabolic process of these bioactive peptides in vivo . Bottger et al incubated eight peptides with the blood, plasma, and serum, and they found that the modified peptide with its C-terminal amide was more stable in the blood, plasma and serum.…”
Section: Resultsmentioning
confidence: 99%
“…We anticipate the development of selective PTHrP/PTH1R modulators that adopt the advantages of emerging chemical modalities to overcome the limitations of current ones. For example, structural modifications including incorporation of unnatural amino acids (i.e., D-AA), retro-inverso isomers, N-methylation, or stapling reactions between amino acids may result in better PTH1R binding molecules with comparable binding specificity/selectivity and in vivo stability [ 125 ]; PTH1R inhibitors can be conjugated with molecules targeting E3 ligase or lysosome to induce PTH1R degradation via proteasome or lysosome; a DNA aptamer interrupting PTHrP binding, but not affecting PTH binding to PTH1R, can be screened de novo based on the cryo-EM structures, and the aptamers can be further optimized for in vitro and in vivo safe delivery. Our prospective targeting approaches against PTHrP/PTH1R are depicted in Figure 4 .…”
Section: Discussionmentioning
confidence: 99%
“…For example, antioxidant peptides Tyr-Phe-Cys-Leu-Thr and Gly-Leu-Leu-Leu-Pro-His were reported to transport via not only paracellular pathway across tight junctions but also transcytosis . After absorption, bioactive peptides may be degraded by proteases and peptidases in the blood or enzymatically hydrolyzed in the kidney and liver before reaching the organs throughout the body . However, due to the limited amount of research, the absorption, distribution, metabolism, and excretion of bioactive peptides are still unclear. , …”
Section: Mechanism Of Antisarcopenic Peptides In Alleviating Sarcopeniamentioning
confidence: 99%
“…After absorption, bioactive peptides may be degraded by proteases and peptidases in the blood or enzymatically hydrolyzed in the kidney and liver before reaching the organs throughout the body . However, due to the limited amount of research, the absorption, distribution, metabolism, and excretion of bioactive peptides are still unclear. , …”
Section: Mechanism Of Antisarcopenic Peptides In Alleviating Sarcopeniamentioning
confidence: 99%
See 1 more Smart Citation